Navigation Links
NOVIS Announces Appointment of John J. Arlotta as Chairman
Date:10/23/2008

MIAMI, Oct. 23 /PRNewswire/ -- NOVIS Pharmaceuticals, Inc. today announced that healthcare industry veteran John J. Arlotta has been appointed Chairman of the Board. The appointment was announced during the most recent NOVIS Board of Directors meeting and is effective immediately.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081023/CLTH043LOGO )

"I am very excited to take on this role at NOVIS, and I look forward to helping the company achieve its aggressive strategic goals," said Mr. Arlotta. He added, "I am also very impressed with the management team that has been assembled at NOVIS, and I am excited to have the opportunity to assist them in achieving their vision for the company."

Thomas E. Burke III, President and CEO of NOVIS, said, "We are thrilled and honored to have John join our team. John's career has been exemplified by dramatic growth and an unwavering commitment to patient safety and customer service. I look forward to working with John as we create new partnerships, expand our product line, and further establish NOVIS as the vendor of choice for specialty therapeutics."

Mr. Arlotta has more than 30 years experience in the pharmacy services industry, most recently as Chairman, President and CEO of Coram Inc., a leading provider of specialty infusion and pharmacy distribution services that was acquired by Apria Healthcare Group in December 2007. Previously, he served as the President and CEO of NeighborCare, a Baltimore based public company and provider of pharmaceutical products and services to nursing homes. Mr. Arlotta's experience also includes five years as President and COO of Caremark Rx, ten years as owner and manager of HealthCall, and fifteen years at Baxter International. Mr. Arlotta is a graduate of the University of Notre Dame, is married with three adult children and currently lives in Denver, Colorado. In 2008, Mr. Arlotta purchased the Minnesota Swarm professional indoor lacrosse franchise.

About NOVIS Pharmaceuticals, Inc.

NOVIS Pharmaceuticals is a leading distributor of specialty therapeutics. Through superior customer service and innovative technology solutions, the company provides safe, timely and economical access to critical medications. Based in Miami, FL, and supported by strategically located centers throughout the U.S. and Puerto Rico, NOVIS is a privately held company. For more information, please visit http://www.novispharma.com .


'/>"/>
SOURCE NOVIS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. Renovis Reports Third Quarter 2007 Financial Results
3. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
4. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
5. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
6. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
7. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
8. Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec
9. Renovis Stockholders Approve Acquisition by Evotec
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that in a published evaluation of multiple immunoassay-based threat detection technologies ... of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):